Insight
2025: The year IVF innovation went from lab to life
By FinDBest IVF
The year 2025 will be remembered as a pivotal moment in reproductive medicine—a year when artificial intelligence moved from proof-of-concept to regulatory approval, when automation transformed from aspiration to clinical reality, and when genomic technologies began delivering on their promise of precision fertility care.
At FinDBest IVF, we’ve tracked these developments week by week through our Monday’s 5 news series, and as the year draws to a close, we’re taking stock of the innovations that defined 2025 and will shape the future of IVF/ART.
This review highlights the year’s most significant advancements across six key domains: AI-powered embryo selection, automation & robotics, male infertility solutions, non-invasive diagnostics & precision medicine, regulatory & industry milestones, and emerging research & clinical innovation.
Each represents not just technological progress, but tangible improvements in clinical outcomes, patient experience, and global access to fertility care.
- AI-Powered Embryo Selection: From Algorithms to Approvals
The Regulatory Breakthrough
2025 marked the transition of AI-powered embryo selection from research tool to clinically validated medical device.
The most significant milestone came in October when Alife Health, led by CEO Melissa Terán alongside Paxton Maeder-York and Dr. Emre Seli, received CE Mark approval under the EU Medical Device Regulation (MDR) for its Embryo Predict™ system.
This represented the first time an AI-based embryo selection platform achieved the stringent requirements of post-2021 European regulation, setting a new benchmark for transparency, clinical validation, and real-world performance.
The deep learning model, trained on thousands of time-lapse embryo videos, predicts implantation potential with precision that potentially reduces time to pregnancy and minimises failed transfers.
Federated Learning: Privacy Meets Performance
A groundbreaking study published in Nature Communications Medicine introduced federated task-adaptive learning for personalized embryo selection.
Led by Prof. Guangyu Wang, this approach allows AI models to learn across multiple IVF centers without centralising patient data—addressing one of the field’s most critical challenges: privacy-preserving collaboration.
The technology keeps data at individual clinics while building superior prediction models, achieving better live-birth prediction compared to centralised approaches while maintaining built-in data protection.
Metabolic Imaging: The Next Frontier
While morphology-based AI dominated headlines, Lumiris Technologies’ Metaphor™ system introduced a paradigm shift: using AI-driven hyperspectral imaging to assess embryo metabolic stress.
Unlike traditional time-lapse systems that evaluate visual development, Metaphor analyzes the metabolic “fingerprint” of embryos through hyperspectral microscopy combined with AI, offering insights into cellular health that are invisible to the human eye.
This metabolic stress assessment potentially identifies embryos with better implantation potential beyond what visual assessment can detect.
- Automation & Robotics: The Smart Lab Revolution
World’s First Robot-Born Babies
August 2025 brought a watershed moment: the birth of the world’s first babies conceived through AI-powered, robot-controlled IVF.
Columbia University Fertility Center, working with Conceivable Life Sciences under the leadership of Dr Zev Williams, CEO Alan Murray, and Chief Knowledge Officer Dr Stephanie Kuku, successfully delivered 19 healthy infants using an autonomous system that handled sperm selection, fertilization, and embryo culture with minimal human intervention.
The AI-driven robotic platform manages the full IVF workflow from sperm analysis to embryo culture, demonstrating that automated reproductive medicine can deliver clinical outcomes that match or exceed traditional approaches.
The 19 healthy live births validate that automation reduces variability, increases efficiency, and potentially democratizes access to expert-level IVF care.
Overture Life: Automation Reaches Critical Mass
Overture Life, founded by Martin Varsavsky and led by CEO Hans Gangeskar with scientific direction from Santiago Munné and contributions from Dr José A. Horcajadas, emerged as 2025’s automation leader.
The company’s DaVitri platform—the world’s first microfluidics-based automated vitrification system—launched European preorder waitlist in September and opened a Dallas clinical lab and robotics HQ in October.
DaVitri standardizes vitrification protocols for embryos and oocytes, reducing operator dependency and improving reproducibility across IVF labs.
Beyond DaVitri, Overture Life continues developing an integrated suite including automated sperm selection and ICSI modules toward a fully integrated smart lab.
AutoIVF Secures Major Investment
Vitrolife’s investment in AutoIVF signaled mainstream industry validation of automation technologies, positioning the Swedish giant to integrate automated solutions across its global distribution network.
The investment accelerates commercialization of AutoIVF’s automation platform, which enhances consistency and affordability while reducing outcome variability—making IVF more cost-accessible without sacrificing quality.
- Male Infertility: AI, Robotics & Precision Selection
AI Rescues 18-Year Infertility Journey
One of 2025’s most compelling stories came from Columbia University, where Dr Zev Williams and his team used the STAR system (Sperm Tracking and Recovery) to help a couple achieve pregnancy after 18 years of trying.
The AI identified 44 viable sperm in under 2 hours from an azoospermic sample—sperm that conventional methods had missed.
This technology transforms outcomes for severe male factor infertility by detecting sperm conventional analysis overlooks, developed over five years to address one of fertility’s most challenging clinical scenarios.
T’easy: AI Meets Testicular Biopsy
UZ Brussel introduced “T’easy,” an AI-powered system that detects sperm in testicular biopsies within minutes, dramatically reducing the time required for male infertility diagnosis and improving success rates in testicular sperm extraction procedures.
The real-time AI analysis of testicular biopsy samples completes in minutes instead of hours, improving TESE success rates while reducing patient time under anesthesia—a practical efficiency gain that directly benefits patient comfort and clinical workflow.
Research Debunks Antioxidant Myth
A major randomised clinical trial published in JAMA Network delivered important negative findings: antioxidant supplements (Impryl®) showed no benefit for male fertility in IVF cycles.
Led by researchers Wiep de Ligny and Jan-Peter de Bruin, the SUMMER trial found no statistically significant improvement in pregnancy or live birth rates, challenging widespread clinical practice and emphasising the need for evidence-based approaches over routine supplement prescription.
- Non-Invasive Diagnostics & Precision Medicine
First-Ever Footage of Human Embryo Implantation
Scientists achieved a historic first in August 2025: capturing real-time 3D video of a human embryo implanting in the uterus.
Published in The Guardian and detailed in Human Reproduction by Oxford University Press, this groundbreaking imaging revealed the embryo’s active, invasive role in implantation—offering unprecedented insights into one of reproduction’s most critical yet mysterious processes.
The advanced 3D imaging technology captured embryo-endometrial interaction dynamics that may inform new interventions to improve implantation rates.
Optical Genome Mapping for Pregnancy Loss
Optical Genome Mapping (OGM) emerged as a superior alternative to traditional cytogenetic methods for diagnosing chromosomal causes of recurrent pregnancy loss.
Highlighted in Contemporary OB/GYN, this high-resolution genome mapping technology detects structural chromosomal variants faster and with more detail than karyotyping or chromosomal microarray.
OGM outperforms traditional cytogenetics in identifying miscarriage-related genetic abnormalities, accelerating diagnosis in recurrent pregnancy loss cases and enabling earlier targeted interventions.
Spent Culture Media: The Non-Invasive Biomarker
A comprehensive review of 49 studies, published in EMJ Reproductive Health, highlighted spent embryo culture media as a promising source of non-invasive biomarkers for embryo viability.
Metabolomic analysis of culture media—examining glucose, amino acids, fatty acids, and other metabolites—offers embryo assessment without biopsy.
While the review emphasizes the need for unified methodologies to advance clinical application, the approach could reduce reliance on invasive PGT-A while providing complementary embryo viability insights.
- Regulatory & Industry Milestones
Australia Calls for National ART Regulation
A coalition of Australian researchers and legal experts issued a landmark call for national IVF/ART regulatory reform, recommending establishment of an independent commission, harmonised accreditation standards, and unified governance across fertility clinics.
The review, detailed in the Surrogacy & Fertility Bulletin by Sarah Jefford, highlighted system fragmentation as a key barrier to quality and safety.
The proposal reflects a global trend toward strengthened fertility clinic governance, addressing inconsistencies that currently exist across state-level regulation.
Monash IVF Leadership Transition
Monash IVF appointed Dr Victoria Atkinson, currently CMO at Healthscope, as its next MD & CEO effective May 2026.
The appointment reinforces Monash IVF’s commitment to clinical governance and patient-safety-led transformation as the group enters a new operational phase focused on quality outcomes and systematic improvement.
ASRM Framework for Embryo Testing Innovation
The American Society for Reproductive Medicine (ASRM) published a comprehensive framework in Fertility & Sterility outlining a staged pathway for embryo testing technologies from early innovation to validated clinical practice.
The framework emphasises evidence strength, reproducibility, and patient-centered outcomes—providing critical guidance for labs, regulators, and device manufacturers navigating the journey from innovation to clinical deployment.
Global Regulatory Tightening: MDR, FDA, NMPA
FinDBest IVF partnered with Femtech World to publish a comprehensive analysis of global regulatory shifts affecting IVF innovation in 2025.
The review examined how device and diagnostic regulation is tightening across major markets.
In the EU, MDR is in full effect with IVF consumables now classified as Class IIb or III, requiring stricter UDI compliance and post-market surveillance.
The FDA has increased scrutiny of AI/ML-based devices with updated premarket pathways. China’s NMPA now requires UDI cloud integration and cybersecurity risk reports for connected IVF devices.
These changes mean approval timelines have extended 6-12 months with significantly increased documentation requirements, affecting every manufacturer seeking global market access.
Professional Development & Industry Recognition
The ASRM Society of Reproductive Biologists & Technologists (SRBT) launched the Nexpring Health Diarmaid Douglas-Hamilton Memorial Scholarship, honouring a legendary figure in ART and supporting the next generation of embryologists and lab technicians.
The scholarship expands access to advanced reproductive technology education, ensuring continued innovation through professional development of emerging ART leaders.
- Emerging Research & Clinical Innovation
Organoids: Mini Placentas & Ovaries
Dr. Margherita Turco’s pioneering work with lab-grown reproductive tissues—including “mini placentas” and ovarian organoids—is reshaping fertility research.
Featured in Nature, these patient-derived cells grown into 3D placental and ovarian tissue models enable unprecedented study of implantation biology and early ovarian development.
The 3D cellular models allow research into implantation and ovarian biology previously impossible with traditional 2D cultures, potentially revealing new therapeutic targets for implantation failure and ovarian disorders.
Mitochondrial Replacement: Three-Person IVF
Research published in Science Daily reported successful live births using mitochondrial donation techniques (three-person IVF), preventing transmission of mitochondrial disorders.
The technology replaces mother’s mitochondria in eggs with healthy donor mitochondria, offering a reproductive option for women carrying mitochondrial disorders.
Early monitoring showed no adverse effects in infants, though long-term studies continue to track outcomes.
Polygenic Embryo Screening: The Ethical Frontier
Orchid’s embryo screening services gained attention—and ethical scrutiny—for offering polygenic risk score analysis for traits including IQ, heart disease risk, and longevity.
The Washington Post reported that high-profile individuals including Elon Musk are using the technology, raising significant bioethical concerns about embryo selection beyond medical disease prevention.
The multi-gene risk scoring for complex traits extends embryo screening from single-gene disorders to polygenic conditions, sparking urgent questions about trait selection, equity, and societal implications.
Cloud-Based EMR Revolution
eIVF, led by CEO Nimesh Shah, launched CloudFlex, a HIPAA-compliant cloud-based electronic medical record solution that eliminates onsite servers and large upfront investments.
The platform integrates EMR software with infrastructure management into a single hosted solution, reducing capital investment and IT maintenance burden for clinics while ensuring data security—accelerating digital transformation particularly for smaller fertility practices.
Next-Generation FSH Development
Granata Bio and Georgetown Equity Partners announced a joint venture to develop next-generation recombinant follicle-stimulating hormone (FSH) formulations.
Led by Ali Hussein, Mark De Ridder, CEO Evan Sussman, Dr. William Schoolcraft, and researcher Dr T. Rajendra Kumar, the initiative aims to improve ovarian stimulation efficiency and affordability across IVF protocols through novel recombinant FSH with improved pharmacokinetics.
Validating AI: Clinical Variables and Morphokinetics
A significant study in Reproductive BioMedicine Online examined how clinical variables affect embryo morphokinetics and AI quality scoring.
The research, led by Jorge Ten and colleagues including M. Carmen Tio, Pedro Pini, Andrea Bernabeu, Rafael Bernabeu, and Klaus Wiemer at Instituto Bernabeu, provides critical insights into factors that influence AI-based embryo assessment systems.
The analysis helps embryologists understand when AI predictions may need clinical context adjustment, informing appropriate use and interpretation of AI embryo selection tools.
Predicting Oocyte Retrieval Outcomes
Research by Julia K Bosdou, Christos A Venetis, Leonidas Zepiridis, Katerina Chatzimeletiou, Grigorios Grimbizis, and Efstratios M Kolibianakis investigated whether minimum oocyte yield could be estimated from follicle diameter on trigger day.
The cohort study, published in Reproductive BioMedicine Online, provides practical insights for clinicians counseling patients on expected outcomes, helping set realistic expectations and optimize trigger timing.
Looking Forward: Implications for 2026
As we move into 2026, several clear trends emerge from 2025’s innovations.
Regulatory maturity means the AI and automation technologies that struggled for regulatory approval in previous years have now successfully navigated MDR, FDA, and other frameworks.
This regulatory maturity will accelerate commercial deployment and clinical integration, making 2026 the year these technologies move from early adopters to mainstream practice.
Automation as standard of care is no longer aspirational.
With 19 healthy robot-IVF babies born and major platforms like Overture Life’s DaVitri reaching commercialisation, automation is transitioning from experimental to standard practice, particularly for high-volume processes like vitrification and sperm selection.
Privacy-preserving AI addresses one of the field’s most significant barriers through federated learning and other privacy-preserving techniques.
These approaches enable multi-center collaboration without centralizing sensitive patient data, solving both technical and regulatory challenges.
Evidence-based medicine remains essential.
Negative findings like the SUMMER trial’s antioxidant results remind us that rigorous clinical trials are critical, even for widely adopted practices. The field continues maturing through careful validation rather than assumption.
Ethical frameworks become urgent as technologies like polygenic screening demand development of ethical guidelines, professional standards, and potentially regulatory guardrails to ensure responsible innovation.
The industry must proactively address these questions rather than reacting to public concern.
Conclusion
2025 will be remembered as the year IVF innovation achieved critical mass—when AI earned regulatory approval, when robots assisted in live births, when non-invasive diagnostics began replacing invasive procedures, and when automation moved from aspiration to commercial reality.
But perhaps most importantly, 2025 demonstrated that technological innovation alone is insufficient.
Success requires regulatory navigation, clinical validation, ethical frameworks, and—crucially—the distribution partnerships that transform laboratory breakthroughs into global patient access.
At FinDBest IVF, we’re proud to have chronicled these innovations through our Monday’s 5 series throughout 2025, and we’re committed to connecting the innovators shaping reproductive medicine with the global network that will bring their solutions to the patients who need them.
The future of family building is being written today. Join us in making it accessible to all.
About FinDBest IVF
FinDBest IVF is the leading B2B marketplace connecting IVF medical device manufacturers with vetted distributors and market expansion service providers worldwide.
Our platform serves manufacturers, distributors, and fertility clinics across 150+ countries, facilitating partnerships that accelerate innovation and improve patient outcomes globally.
Follow our Monday’s 5 news series: https://findbestivf.com/ivf-market_news/
Connect on LinkedIn: https://www.linkedin.com/company/findbest-ivf/
#IVFInnovation #FertilityTech #ART #ReproductiveMedicine #MedTech #FemTech #AIinHealthcare #Automation #Robotics #2025Review #FindBestIVF
News
Bridging the metabolic wealth gap: The telehealth platform bypassing insurance to democratise care
As weight-loss treatments remain locked behind prohibitive paywalls, a new direct-pay initiative is cutting costs in half for low-income patients, and it could provide a new blueprint for health equity.
It is one of the most persistent, frustrating paradoxes in modern healthcare: the medical innovations most capable of addressing widespread chronic conditions are overwhelmingly priced out of reach for the populations most vulnerable to them.
Nowhere is this more evident than in the current landscape of metabolic health and weight management.
As state governments and insurance providers increasingly restrict coverage for advanced weight-loss medications due to skyrocketing costs, a stark dividing line has emerged. Clinical need is no longer the primary factor in who receives treatment. Affordability is.
This financial barrier disproportionately impacts women, who not only face high rates of metabolic conditions but also frequently serve as the primary caregivers in their households.
For a single mother managing childcare, grueling work hours, and the relentlessly rising cost of living, personal well-being is often the first casualty of a tight budget.
These patients are forced into a holding pattern, watching their conditions progress year after year while highly effective, life-changing treatments remain separated from them by a paywall.
Now, a telehealth platform called Amble Health is attempting to dismantle that wall by bypassing the traditional insurance apparatus entirely.
A Structural Shift for Access
Today, Amble Health announced the launch of the Amble Cares Program, a national initiative designed to cut the cost of medical weight-loss treatments in half for low-income Americans.
The programme arrives at a critical inflection point.
Today, roughly one in eight U.S. adults have utilized advanced metabolic medications, according to a recent KFF Health Tracking Poll.
This surge in adoption has driven a fundamental shift in preventative care, but the distribution of that care has been deeply uneven.
Through the Amble Cares Program, eligible patients can access comprehensive medical weight-loss programmes, which may include prescription medications if clinically appropriate, at up to 50 per cent below standard rates.
To ensure the discounts reach the intended demographic, eligibility is determined by an independent, third-party verification partner, based on verified financial need.
The programme explicitly prioritises individuals and families with limited disposable income, including parents and guardians whose financial flexibility is tied up in providing for dependents.
Once verified, patients are connected directly to licensed clinicians to begin treatment immediately, stripping away the friction of waiting periods.
“Healthcare should not be a luxury item,” said Joey Stiver, CEO of Amble Health. At Amble, we believe that a patient’s zip code or income shouldn’t dictate their metabolic health outcomes.
“The Amble Cares Program is our direct response to the cost of living crisis, moving beyond talk of ‘affordability’ to actually delivering it to the people the traditional system has left behind.”
The Direct-Pay Trade-Off
However, this rapid, lower-cost access comes with a significant structural trade-off.
To achieve these price reductions and eliminate the administrative delays, denials, and red tape associated with traditional healthcare, Amble Health operates strictly as a direct-pay platform.
This means participants cannot use outside coverage. The programme does not accept Medicaid, Medicare, commercial insurance, or even HSA/FSA funds.
For some patients, being entirely locked out of utilizing their existing health benefits may present a new kind of hurdle.
But for those who have already found themselves abandoned by traditional coverage networks, facing outright denials, unnavigable prior authorisations, or insurmountable deductibles, the direct-pay model offers a predictable, transparent alternative to a broken system.
Ultimately, the Amble Cares Program is making a bold bet: that the most efficient way to deliver equitable healthcare to disenfranchised populations isn’t to fix the traditional insurance system, but to innovate entirely around it.
The Women and Equalities Committee (WEC) has warned against “financial half measures” on women’s health as the government published its response to the report.
Ministers launched the renewed Women’s Health Strategy in April after the committee’s March report concluded it was not convinced that the menstrual and gynaecological needs of young women and girls had been sufficiently prioritised in wider healthcare reforms.
It followed the committee’s 2024 “medical misogyny” report, which found women with painful reproductive health conditions such as endometriosis, adenomyosis and heavy menstrual bleeding were frequently finding their symptoms “normalised” and their “pain dismissed” when seeking help.
In both reports, MPs called on the government to recognise the benefits of increased investment in early diagnosis and treatment of women’s reproductive health conditions and provide additional funding needed to transform the support available to millions of women.
In its response, published on 26 May as a command paper, the Department of Health and Social Care outlined action on reducing gynae waiting times, ensuring procedures are conducted with women’s full consent and adequate pain relief, and improving access to contraception for menstrual healthcare in line with the committee’s recommendations.
It said: “The government agrees with the committee’s overarching findings and recommendations for improving women’s health outcomes and experiences.
“We acknowledge the impact that menstrual health conditions can have on women’s lives, relationships, and participation in education and the workforce.
“We recognise that more needs to be done to support women with menstrual health conditions, particularly around listening to women, improving information and education, and enhancing patient experience.”
However, there was no commitment to increase school nurse provision, no measurable actions and targets on countering online misinformation, no new commitments to end inappropriate censorship of women’s online health content, and no further initiatives on tackling racial discrimination or understanding the menstrual wellbeing needs of young disabled and Deaf women.
The response comes after analysis by The Times suggested the government is allocating 60 per cent more funding to its men’s health strategy than to its renewed strategy for women’s health.
Sarah Owen, chair of the Women and Equalities Committee and Labour MP, said: “WEC’s 2024 ‘medical misogyny’ report warned 18 months ago of women in unnecessary pain and undiagnosed for years and called on the Government to recognise the benefits of increased investment in early diagnosis and treatment.
“Our follow up report this March cautioned girls’ and women’s health are not being sufficiently prioritised in system-wide NHS reforms, while initiatives which have proven to be successful in reducing waiting lists and improving women’s healthcare access, such as women’s health hubs, risked being scaled back or discontinued.
“While it’s welcome to see a focus on tackling ‘medical misogyny’ in April’s renewed Women’s Health Strategy and an emphasis on women’s voices being heard, this must be backed by adequate funding, not financial half measures, particularly when compared to men’s health.
“Significant questions remain following today’s response publication over the adequacy of investment being provided, including for workforce training, menstrual health education in schools, research and additional ring-fenced funding for women’s health hubs to deliver services within the emerging neighbourhood health framework.
“There are both opportunities and risks when it comes to increasing use of technology in women’s healthcare.
“As the Committee’s report set out, social media companies should be held to account for inappropriate and disgraceful ‘shadow banning’ censorship of important women’s health content and there should be a rigorous approach to tackling the risks from ineffective, unsafe and exploitative for-profit FemTech apps.
“The Government should take the problem of ‘shadow banning’ more seriously.
“A strategy which does not fully address the concerns set out in WEC’s report, alongside measurable actions and timescales, will only scratch the surface of the issues facing women’s health.
“WEC will keep a close eye on progress and continue to push for long overdue tangible change for women and girls.”
An early PET scan after one cycle of chemotherapy may help predict how aggressive breast cancer responds to treatment, a study suggests.
Research led by The Institute of Cancer Research, London and King’s College London suggests that an early scan taken after one cycle of chemotherapy could help predict how well a patient’s cancer will respond to treatment.
The study focused on patients with triple-negative breast cancer (TNBC), an aggressive form of the disease in which cancer cells lack receptors for the hormones oestrogen and progesterone, as well as the HER2 protein.
Patients with TNBC are usually treated with chemotherapy prior to surgery. While many respond well, residual disease at surgery, typically around six months later, is associated with a significantly poorer prognosis. Identifying people sooner who are unlikely to respond remains a major clinical challenge.
The research explored whether using PET imaging shortly after treatment begins, rather than relying only on MRI scans later in the treatment process, could provide earlier insight into how a patient’s cancer is responding. Twenty-two patients were recruited, with fourteen undergoing FDG-PET scans before treatment and after the first cycle of chemotherapy.
The findings, published in Clinical Cancer Research, showed that changes seen on PET scans after just one cycle of chemotherapy were strongly associated with subsequent response, including whether there was no detectable cancer, known as a complete response, by the end of treatment. Importantly, early PET response showed stronger associations with treatment outcomes than standard mid-treatment MRI scans in this study.
Being able to identify patients who are not responding well at an early stage could allow clinicians to adjust treatment sooner or consider alternative approaches. These findings may also support future strategies to better tailor treatment intensity to individual patients.
The study also compared two types of PET tracers, FDG and FLT, to determine which was most suitable. While both met the study’s technical criteria, FDG-PET was selected for further evaluation due to its better image quality, greater consistency and wider use in clinical practice.
The research also explored how imaging changes after just one cycle of chemotherapy relate to the body’s immune response to treatment. Biopsies taken before and after the first cycle of chemotherapy showed that an increase in immune cells within the tumour was strongly associated with both early PET changes and improved treatment outcomes.
The researchers emphasise that these findings now need to be validated in larger studies. Future work will aim to confirm these results in broader patient groups and explore more accessible imaging approaches, such as ultrasound, alongside PET and MRI.
Sheeba Irshad, professor of cancer immunology at King’s College London and lead of the Breast Cancer Now KCL Research Unit, said:
“In patients who had PET scans both before treatment and after the first cycle, we found that this early scan could predict whether they were likely to achieve a complete response by the end of treatment. These findings highlight the potential of early imaging to guide treatment decisions, and now need to be validated in larger, modern clinical trials.”
Andrew Tutt, professor of breast oncology at The Institute of Cancer Research, London, said:
“Research that helps us determine early who is already benefitting from standard neoadjuvant chemotherapy and who might benefit from clinical trials to find better treatments is vital. This study shows that FDG-PET may have great value in this regard. We hope to be able to design studies that further investigate and validate these findings.”
The study was supported by funding from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, Breast Cancer Now, Cancer Research UK, and Guy’s and St Thomas’ Charity.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
Motherhood4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Insight4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’
2 Comments